In summary, EZH2 inhibitors upregulate the infiltration of immune cells in the tumor microenvironment and induce reprogramming of immunosuppressive cells, which enhances the antitumor efficacy of PARP inhibitors. This evidence concerns the gene EZH2 and neoplasm.